✦ LIBER ✦

Safety and feasibility of biweekly neoadjuvant gemcitabine, epirubicin, and albumin bound nab-paclitaxel (GEA) in locally advanced breast cancer – results of a phase II study

✍ Scribed by D. Daniel; B. Daniel; R. Inhorn; Y. Naot; J. Zubkus; L. Simons; D. Knauer; V. Trieu; N. Desai; D. Yardley

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety data from a phase II study of neo

✍ D. Yardlev; E. Raefsky; R. Castillo; A. Lahiry; D. Thompson; S. Hanson; C. Meng; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

A Phase II Trial of Dose-Dense Neoadjuva

✍ Denise A. Yardley; John Zubkus; Brooke Daniel; Roger Inhorn; Cassie M. Lane; Eli 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 698 KB

A Phase II Neoadjuvant Trial of Sequenti

✍ André Robidoux; Aman U. Buzdar; Emmanuel Quinaux; Samuel Jacobs; Priya Rastogi; 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 122 KB

A phase II study of epirubicin, cisplati

✍ Kenneth Villman; John F. Öhd; Elisabet Lidbrink; Lena Malmberg; Birgitta Lindh; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 339 KB

Phase II Study of Neoadjuvant Weekly nab

✍ Denise A. Yardley; Eric Raefsky; Raul Castillo; Anup Lahiry; Richard LoCicero; D 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 370 KB

Biweekly docetaxel and gemcitabine as ne

✍ Laura G Estévez; Pedro Sánchez-Rovira; Manuel Dómine; A León; Isabel Calvo; Ana 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 89 KB